Long term study of LDL-c Lowering with Evolocumab: Observational Follow-up after the FOURIER OUTCOMES study (Protocol number: CTC 0173). Long-term post-trial (legacy) beneficial effects have been reported with statins, niacin, hypoglycaemic therapy and fibrates. Whether similar effects are seen after LDL-cholesterol (LDL-c) lowering by PCSK9 inhibition is currently unknown. This study aims to evaluate potential long-term effects of evolocumab treatment in patients who completed the FOURIER OUTCOMES trials, on cardiovascular outcomes.

 

Trial Summary:

Participants will be remotely assessed (via questionnaire) upon entry into FOURIER LEGACY, approximately 6 and 12 months later and then approximately annually to obtain a total of 5 years’ follow-up after the date of last contact in FOURIER OUTCOMES to collect details of cardiovascular hospitalisations, mortality and lipid lowering therapy classes.

Supported By:

University of Sydney; coordinated by NHMRC CTC

Eligibility:

Participants in selected countries who completed the FOURIER OUTCOMES clinical trial.

Registration ID:

Not registered. Non-interventional observational cohort study.

Participation:

Minimum of 10,000 globally.

Australian Lead Group:

NHMRC CTC

Status:

Start-up

Activation Date:

 

Chairs:

Professor Tony Keech

Contact:

fourier.legacy@ctc.usyd.edu.au